Cancer type-specific modulation of mitochondrial haplogroups in breast, colorectal and thyroid cancer by Fang, Hezhi et al.
RESEARCH ARTICLE Open Access
Cancer type-specific modulation of mitochondrial
haplogroups in breast, colorectal and thyroid
cancer
Hezhi Fang
1, Lijun Shen
1, Tao Chen
1, Jing He
1, Zhinan Ding
1, Jia Wei
1, Jianchun Qu
1, Guorong Chen
2, Jianxin Lu
1*,
Yidong Bai
1,3*
Abstract
Background: Mitochondrial DNA (mtDNA) haplogroups and single nucleotide polymorphisms (mtSNP) have been
shown to play a role in various human conditions including aging and some neurodegenerative diseases,
metabolic diseases and cancer.
Methods: To investigate whether mtDNA haplogroups contribute to the occurrence of cancer in a specific Chinese
population, we have carried out a comprehensive case-control study of mtDNA from large cohorts of patients with
three common cancer types, namely, colorectal cancer (n = 108), thyroid cancer (n = 100) and breast cancer (n =
104), in Wenzhou, a southern Chinese city in the Zhejiang Province.
Results: We found that patients with mtDNA haplogroup M exhibited an increased risk of breast cancer
occurrence [OR = 1.77; 95% CI (1.03-3.07); P = 0.040], and that this risk was even more pronounced in a sub-
haplogroup of M, D5 [OR = 3.11; 95%CI (1.07-9.06); p = 0.030]. In spite of this, in patients with breast cancer,
haplogroup M was decreased in the metastatic group. On the other hand, our results also showed that
haplogroup D4a was associated with an increased risk of thyroid cancer [OR = 3.00; 95%CI (1.09-8.29); p = 0.028].
However, no significant correlation has been detected between any mtDNA haplogroups and colorectal cancer
occurrence.
Conclusion: Our investigation indicates that mitochondrial haplogroups could have a tissue-specific, population-
specific and stage-specific role in modulating cancer development.
Background
Mitochondria, known as the cellular power plants, also
regulate cell death and cell proliferation[1]. Mitochon-
dria are under dual genome control. Human mtDNA
encodes 13 essential subunits of the oxidative phosphor-
y l a t i o n( O X P H O S )s y s t e ma sw e l la s2r R N A sa n d2 2
tRNAs used in mitochondrial translation. Alterations in
mtDNA including both mutations and polymorphisms
have the potential of changing the capacity of mitochon-
drial function. In particular, changes in oxidative phos-
phorylation resulting from mitochondrial dysfunction
have long been hypothesized to be involved in
tumorigenesis. To explain the fact that cancer cells were
high in fermentation and low in respiration, Warburg
proposed that cancer originated from a non-neoplastic
cell which adopted anaerobic metabolism as a means of
survival after injury to its respiratory system[2], which
led to the notion that tumors were initiated by persis-
tent damage to the mitochondria[3,4]. Supporting such
idea, changes in the number, shape, and function of
mitochondria have been reported in various cancers [5].
Interestingly, abnormal mtDNA was observed in leuke-
mic myeloid cells using an electron microscope[6,7]
long before DNA sequencing technology was available.
Subsequently, mutations in both the non-coding and
coding regions of the mtDNA have been identified in
various types of cancer [8-10]. * Correspondence: jxlu313@163.com; baiy@uthscsa.edu
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largely lacks recombination[11]. A human mtDNA hap-
logroup is defined by unique sets of mtDNA poly-
morphisms, reflecting mutations accumulated by a
discrete maternal lineage[12]. The haplogroups are asso-
ciated with region-specific mtDNA sequence variation
as a result of genetic drift and/or adaptive selection for
an environment-favored mitochondrial function[13,14].
Difference in redox signaling as a consequence of hap-
logroup-associated oxidative phosphorylation capacity
has been suggested as the molecular mechanism
involved in the haplogroups-associated phenotypes
[15,16]. The haplogroup association studies have been
used to investigate the effect of mtDNA variants on var-
ious complex conditions such as aging[17,18], metabolic
diseases[19,20], neurodegenerative diseases [21,22],
infectious diseases [23,24] and cancer[3,8,9]. In particu-
lar, haplogroups D4a, D5 and D4b2b were reported to
be increased in centenarians in Japanese [25,26], while
D4 was found to be enriched in female and N9 and M9
decreased in a Chinese population in Rugao area[17].
mtSNP at 10398, which is a major diagnostic site for
macro-haplogroups M and N in Chinese population
[27,28], has been implicated in longevity[29], Parkinson’s
disease[30], and breast cancer in various populations in
some seemingly conflicting reports[31-34]. Interestingly,
while reported as enriched in group exhibits longevity,
D4a and D5a were observed to increase susceptibility in
a Chinese population to esophageal carcinoma[35].
To assess the possible contribution of mtDNA hap-
logroup-specific polymorphisms to the prevalence of
cancer in a southern Chinese population, we performed
a case-control study of patients with three of the local
most common types of cancer, breast cancer, thyroid
cancer and colorectal cancer in Wenzhou, Zhejiang Pro-
vince of China.
Methods
Subjects
The number and age information (in years) for the can-
cer patients used in this study: 108 colorectal cancer
patients (mean ± SD 62.98 ± 12.63, median = 64, range
30-88), 104 breast cancer patients (mean ± SD 51.6 ±
10.29, median = 51, range 27-79) and 100 thyroid can-
cer patients (mean ± SD 45.98 ± 12.59, median = 46,
r a n g e2 0 - 8 4 ) .T h ep a t i e n t sw e r er e c r u i t e dw h e nt h e y
were admitted for surgery at the First Affiliated Hospital
of Wenzhou Medical College from May, 2007 to
November, 2008. Histological confirmations of each
cancer type were carried out immediately following each
surgery. Three sets of age, gender and geographically
matched control subjects who had a cancer-free history,
and had no other known diseases which could be asso-
ciated with mitochondrial defects were also recruited at
the Physical Examination Center of the same hospital
from October, 2008 to December, 2008. The numbers
and ages (in years) of controls for each study are as fol-
lows: n = 124 (mean ± SD 60.15 ± 9.3, median = 60,
range 37-84) for the colorectal cancer study, n = 114
(mean ± SD 53.44 ± 11.66, median = 52, range 27-84)
for the breast cancer study, and n = 138 (mean ± SD
47.96 ± 6.64, median = 49, range 27-62) for the thyroid
cancer study. Informed consents were obtained from all
patients and controls according to the regulations set
forth by the ethical committee of Wenzhou Medical
College.
mtDNA sequencing
About 2 ml venous blood was collected from each sam-
ple before surgery and any drug treatment. Total DNA
was extracted using a standard phenol-chloroform
method as described previously[36]. The sequences of
two pairs of primers designed to amplify the mtDNA D-
loop and ND3+tRNA
arg+ND4L region were as follows,
L15792F: TCATTGGACAAGTAGCATCC, H794R:
AGGCTAAGCGTTTTGAGCTG and L9967F:
TCTCCATCTATTGATGAGGGTCT, H10858R: AAT-
TAGGCTGTGGGTGGTTG[37]. PCR was performed
on a Thermal Cycler 170-9703 PCR machine (BIO-
RAD, USA). The PCR conditions were as follows: pre-
denaturation at 95°C for 5 min, then 35 cycles of [94°C
for 30 s, 57°C for 35 s, 72°C for 1 min], and a final
extention at 72°C for 4 min. The PCR products were
purified using the Agarose Gel DNA Fragment Recovery
Kit Ver.2.0 (TaKaRa, Japan) and subsequently sequenced
on an ABI Prism 3730 sequence analyzer.
mtDNA haplogroup and mtSNPs analysis
To assign a mtDNA haplogroup to each sample, all
sequences were compared with the revised Cambridge
Reference Sequence (rCRS)[38] and aligned using the
CodonCode Aligner 3.0.1 (CodonCode Corporation,
USA)[37] software program. Based on the most recent
refined East Asian mitochondrial haplogroup tree
[27,28,39], the initial assignment was performed with
the sequencing information from the D-loop, ND3 and
ND4L regions. When necessary, additional information
was obtained by restriction fragment length polymorph-
ism (RFLP) analysis at sites: 663 (HaeIII), 3394 (HaeIII),
4833 (HhaI), 5178 (AluI) and 9824 (HinfI). With some
samples, the 9 bp deletion at the COII-tRNA
lys junction
was also detected to further identification.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware (version 13.0) (SPSS Inc., Chicago, IL, USA). The
Pearson chi-square test was used to analyze the relation-
ship between the prevalence of haplogroups and
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lysis was also carried out to determine the contributions
of haplogroup and other risk factors to cancer features.
Results
Macro-haplogroups M and N on breast cancer
Macro-haplogroups M and N are major descendents of
L3, a superhaplogroup and an “African Eve” which
shapes all various sub-lineages out of Africa[12,40].
These specific haplogroups could be identified by the
polymorphisms at positions 10400 and 10398 in the
Chinese Han population, where M is defined by T at
10400 and likely exhibits G at 10398 whereas N has A
at 10398 as in the Cambridge Standard sequence[28]
(Figure.1). It was reported that haplogroup N was asso-
ciated with an increased risk of breast cancer in the
Indian population[33]. Interestingly, 10398A in African-
American[31] and 10398G in European-American[34]
populations were both reported to correlate with
increased breast cancer risks.
In a case-control study (CCS) conducted with breast
cancer patients in a southern Chinese population, we
tested the correlation between macro-haplogroups M and
N and breast cancer incidence. We found that haplogroup
M posed a significant risk for breast cancer (OR = 1.77;
95%CI 1.03-3.07; P = 0.040), whereas haplogroup N was
associated with a decreased incidence (OR = 0.56; 95%CI
0.33-0.98; P = 0.040) (Table 1). Following age-adjustment
of the data in a binary logistic regression analysis, the
results became even more significant. Haplogroup M had
a higher occurrence in breast cancer patients (OR = 1.84;
95%CI 1.07-3.20; P = 0.029), whereas haplogroup N was
decreased in frequency (OR = 0.54; 95%CI 0.31-0.94; P =
0.029). We then examined the mtSNP at position 10398,
and found that 10398G was correlated with an increased
incidence of breast cancer (OR = 1.77; 95%CI 1.00-3.14; P
= 0.050), and 10398A showed a protection effect (OR =
0.56; 95%CI 0.32-1.00; P = 0.050) (Table 1). A stronger
influence was revealed after a binary logistic regression
analysis for the age-adjustment for both 10398G (OR =
1.98; 95%CI 1.11-3.53, P = 0.021) and 10398A (OR = 0.51,
95%CI 0.28-0.90, P = 0.021).
We also analyzed some clinical characteristics and
other risk factors for breast cancer in the breast cancer
patients divided among macro-haplogroups M and N.
As shown in Table 2, age is not a contributing factor (P
= 0.838) to the differences we observed in breast cancer
patients with macro-haplogroups M and N. Similarly,
we did not detect a significant difference in Body Mass
Index (BMI) between these patients. Further investiga-
tion of the expression of progesterone receptor (PR) and
estrogen receptor (ER) failed to reveal any difference
between the M and N haplogroups. However, surpris-
ingly we found an enriched presentation of the N hap-
logroup in patients with metastatic breast cancer (P =
0.044). After adjusting with co-variants like age, BMI,
PR and ER expression, N still exhibited a significantly
higher occurrence in the metastatic group (OR = 0.39;
95%CI 0.17-0.94; P = 0.036).
Haplogroup analysis in breast cancer, colorectal cancer
and thyroid cancer patients
We furthered our investigation by performing a more
detailed sub-haplogroup analysis. As described in the
Materials and Methods section, based on the mtSNPs
shown in Figure 1, we were able to assign 104 breast
cancer patients and 114 controls to 12 sub-hap-
logroups. As shown in Table 3, we found haplogroup
D5, a sub-haplogroup of D under M (Figure. 1), dis-
played a significantly higher frequency in breast cancer
Table 1 Effect of macro haplogroup M and N on breast cancer occurrence
Sample Value Haplogroups P value OR (95%CI) 10398 P value OR (95%CI)
M(n) N(n) G A
Cases 104 69 35 0.040* 1.77(1.03-3.07) 76 28 0.050* 1.77(1.00-3.14)
Controls 114 60 54 69 45
P values were estimated by “chi-square test"; (*) indicated statistical significant (P < 0.05). OR indicates odds ratio; 95% CI, 95%confidence interval.
Table 2 Stratification of clinical characteristics in breast
cancer cases with haplogroup M and N
Variable Value Haplogroups P value
M(n) N(n)
Cancer metastasis 0.044*
yes 34 18 16
No 70 51 19
Progesterone receptor (PR) 0.818
PR positive 64 43 21
PR negative 40 26 14
Estrogen receptor (ER) 0.932
ER positive 63 42 21
ER negative 41 27 14
Age 0.838
≤50 49 33 16
>50 55 36 19
BMI 0.832
18-25 55 37 18
>25 or <18 49 32 17
P values were estimated by “chi-square test"; (*) indicated statistical significant
(P < 0.05). BMI, body mass index; BMI ranging18-25 is considered as normal.
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95%CI 1.07-9.06; P = 0.030). This significant correla-
tion remained after age-adjustment of the data in bin-
ary logistic regression analysis (OR = 3.13; 95%CI:
1.07-9.13; P = 0.037).
To determine if the coincidence of a specific mtDNA
haplogroup with breast cancer indicates a general role
in tumorigenesis in the southern Chinese population, we
extended our studies to two other common cancer types
in the Wenzhou area, colorectal cancer and thyroid can-
cer. Similar case-control studies were conducted on col-
orectal cancer and thyroid cancer patients. As shown in
Table 3, unlike what we observed for breast cancer,
there was no correlation between haplogroups M, N or
D5 and occurrences of these cancers. However, our
results revealed that haplogroup D4a, a sub-haplogroup
of D4, which shares the same ancestry of D and M with
D5 (Figure. 1), had a significantly higher frequency in
thyroid cancer patients relative to control subjects (OR
= 3.00; 95%CI 1.087-8.29; P = 0.028). After adjusting the
data for age and gender in binary logistic regression
analysis, the observed difference between cases and con-
trols remained significant (OR = 3.18; 95%CI 1.11-9.11;
P = 0.031). Nevertheless, no significant correlation has
been detected between any mtDNA haplogroups and
colorectal cancer occurrence (Table 3).
mtSNP and combinations of mtSNPs in breast cancer,
colorectal cancer and thyroid cancer patients
To determine the incidence of individual mtSNPs within
haplogroups D4a and D5 in breast or thyroid cancer
patient samples, we performed a stepwise investigation
of the formation of the D5 and D4a sub-haplogroups
and examined their potential correlation with cancer
occurrences. As shown in Table 4, the combination of
10400T and 489C, which mostly determined macro-hap-
logroup M in the Chinese Han population, was asso-
ciated with an increased breast cancer incidence. An
additional 16362C, which mostly further defined the
D plus G haplogroups, somehow negated such a correla-
tion, whereas 10397G, which helped to determine D5,
restored the observed association with an increased risk
of breast cancer. Individually, only 10398G (people with
10397G all belong to this group) exhibited an increased
frequency in breast cancer patients relative to control
subjects. For thyroid cancer, the combination of 16362C
and 16129A, both in the highly variable area of the D-
loop region, exhibited a significant correlation with can-
cer incidence.
In addition, all of the mtSNPs in the D-loop region,
which were not utilized to determine the haplogroups
and identified with a frequency of more than 5% in this
study, were also analyzed. As shown in Table 5, none of
Figure 1 Classification of 12 mtDNA haplogroups in subjects of three case-control studies. The defining sites[38] (as compared with the
revised CRS) utilized in this study are listed in the branches. “d” indicates a deletion; “9 bpd” indicates a 9 bp deletion in the intergenic mtDNA
region between nucleotides 8195-8316[53].
Fang et al. BMC Cancer 2010, 10:421
http://www.biomedcentral.com/1471-2407/10/421
Page 4 of 10Table 3 Effect of haplogroups on breast, colorectal and thyroid cancer occurrences
Haplogroup CCS of breast cancer P value CCS of colorectal cancer P value CCS of thyroid cancer P value
Controls Cases OR Controls Cases OR Controls Cases OR
(N = 114) (N = 104) (95%CI) (N = 125) (N = 108) (95%CI) (N = 138) (N = 100) (95%CI)
M 60 69 1.77(1.03-3.07) 0.040* 61 53 1.01(0.60-1.69) 0.967 70 55 1.19(0.71-1.99) 0.514
D 26 28 1.25(0.67-2.31) 0.482 32 26 0.92(0.51-1.67) 0.788 34 33 1.51(0.85-2.66) 0.157
D4 21 15 0.75(0.36-1.54) 0.427 23 19 0.95(0.48-1.85) 0.873 26 27 1.59(0.86-2.94) 0.135
D4a 6 4 0.72(0.20-2.63) 0.617 9 6 0.76(0.26-2.20) 0.610 6 12 3.00(1.09-8.29) 0.028*
D5 5 13 3.11(1.07-9.06) 0.030* 9 7 0.89(0.32-2.49) 0.829 8 6 1.04(0.35-3.09) 0.948
G 2 7 4.04(0.82-19.91) 0.065 3 0 - 0.105 3 1 0.46(0.05-4.44) 0.487
M8 8 15 2.23(0.91-5.51) 0.075 8 9 1.33(0.49-3.58) 0.571 11 6 0.74(0.26-2.06) 0.560
M7 16 8 0.51(0.21-1.25) 0.135 13 9 0.78(0.32-1.91) 0.591 15 11 1.01(0.44-2.31) 0.975
M10a 2 5 2.83(0.54-14.90) 0.202 1 3 3.54(0.36-34.57) 0.246 3 0 - 0.138
N
A 10 4 0.42(0.13-1.37) 0.138 10 9 1.05(0.41-2.68) 0.926 11 9 1.14(0.46-2.87) 0.778
N9 3 4 1.48(0.32-6.78) 0.611 5 7 1.66(0.51-5.40) 0.393 4 5 1.76(0.46-6.74) 0.402
R 41 27 0.62(0.35-1.12) 0.111 48 36 0.80(0.47-1.37) 0.422 52 27 0.61(0.35-1.07) 0.084
B 23 14 0.69(0.33-1.44) 0.322 24 20 0.96(0.50-1.85) 0.895 26 16 0.82(0.41-1.63) 0.570
B4 16 8 0.51(0.21-1.25) 0.135 17 9 0.58(0.25-1.36) 0.203 19 9 0.62(0.27-1.43) 0.260
B5 7 5 0.77(0.24-2.51) 0.667 7 11 1.91(0.71-5.12) 0.191 7 7 1.41(0.48-4.15) 0.533
F 13 11 0.92(0.39-2.15) 0.846 19 16 0.97(0.47-2.00) 0.935 22 11 0.65(0.30-1.41) 0.276
P values were estimated by “chi-square test"; (*) indicated statistical significant (P < 0.05). OR indicates odds ratio; 95% CI, 95%confidence interval.
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0them displayed significant association with the occur-
rence of either of the cancer types.
Discussion
In this study, a total of 312 cancer patients (104 with
breast cancer, 108 with colorectal cancer and 100 with
thyroid cancer) and their matched control subjects were
analyzed for the mitochondrial haplogroups and some
related mtSNPs. In the Wenzhou area, breast cancer
ranks number one in cancer occurrence among females,
as in the other regions of the world. Thyroid cancer
ranks number one in the age group of 15-34, and colon
cancer tops liver, lung and stomach cancers, in cancer
patients under 15 years old, both indicating a genetic
predisposition[41]. An age and regional matched study
increased our chances of discovering a contribution
from mtDNA.
The first finding of our study is that macro-hap-
logroup M has an increased frequency in breast cancer
patients relative to controls, and intriguingly, breast can-
cer patients in macro-haplogroup N are more likely to
exhibit metastatic tumors. Previously, a similar CCS
with 124 sporadic breast cancer patients and 273 con-
trols, together with analysis of 2334 individuals belong-
ing to 18 regions in India, led to the proposition that
mtSNP 10398A imparted haplogroup N with an
increased risk for breast cancer[33].
A10398G is probably one of the best studied mtSNPs,
in particular with respect to its potential effect on
tumorigenesis. Noticeably, A10398G changes a threo-
nine residue (A allele) to an alanine (G allele) at the
C-terminus of the ND3 subunit of respiratory complex
I. Using the cybrids system, it was reported that the clo-
sely linked 8701A/10398A mtSNPs were associated with
a lowered mitochondrial matrix pH, and at the same
time an increased basal level of mitochondrial calcium
and cytosolic calcium response to histamine[42].
A series of epidemiological investigations of neurode-
generative diseases like Parkinson’s disease[30], Alzhei-
mer’s disease[43], and amyotropic lateral sclerosis (ALS)
[44] suggested that the 10398A allele is associated with
the degenerative phenotype.
In a large population-based CCS with 654 cases and
605 controls, African-American women with the
10398A allele were shown to have a significant risk of
invasive breast cancer, but such a correlation was not
observed in white women[31]. In a separate CCS with
156 unrelated European-American women with familial
breast cancer and 260 controls, 10398G was associated
with an increased risk of breast cancer[34]. An indepen-
dent investigation carried out with a Polish breast can-
cer population also suggested 10398G as an inherited
predisposition factor for the development of breast can-
cer[45]. However, other studies of either African-Ameri-
can females[46] or Spain and Canary Islands women[47]
failed to confirm a role for mtSNP at 10398 in breast
cancer development. Nevertheless, 10398G was found as
a risk factor in oral cancer among Indian smokers[48].
To reconcile these seemingly conflicting results, based
on our own data, we proposed that the combination of
certain mtDNA haplogroups or mtSNPs (in this case,
10398A or G) with other nuclear encoded factors (some
potentially tissue-specific), could play a role in tumori-
genesis. The net result could be either alteration of cal-
cium or redox signaling. It is also important to note
that the enhanced generation of reactive oxygen species
(ROS), which has been suggested by several investigators
as a likely underlying mechanism by which mitochon-
drial haplogroups and mtSNPs play a role in cancer
development[8,25,31,34], could both activate an onco-
genic pathway which would lead to being a risk factor
for cancer occurrence, or activate the apoptotic reaction,
which could display a protective effect in the late stages
of cancer development. Other determining factors in
Table 4 Effect of D4a and D5 determining mtSNPs on breast cancer and thyroid cancer
mtSNP CCS of breast cancer P value CCS of thyroid cancer P value
Controls Cases OR Controls Cases OR
(N = 114) (N = 104) (95%CI) (N = 138) (N = 100) (95%CI)
C10400T (T489C) 60 69 1.77(1.03-3.07) 0.040* 70 55 1.19(0.71-1.99) 0.514
T16362C+C10400T(T489C) 30 35 1.42(0.79-2.54) 0.237 38 36 1.48(0.85-2.57) 0.164
A10397G+T16362C+C10400T(T489C) 4 13 3.93(1.24-12.46) 0.013* 6 6 1.40(0.44-4.49) 0.565
G16129A+T16362C+C10400T(T489C) 6 4 0.72(0.20-2.63) 0.617 6 12 3.00(1.09-8.29) 0.028*
A10397G+C10400T(T489C) 5 13 3.11(1.07-9.06) 0.030* 8 6 1.04(0.35-3.09) 0.948
A10397G 5 13 3.11(1.07-9.06) 0.030* 8 6 1.04(0.35-3.09) 0.948
A10398G 69 76 1.77(1.00-3.14) 0.050* 74 66 1.08(0.64-1.83) 0.766
T16362C 37 37 1.15(0.66-2.01) 0.627 50 43 1.33(0.78-2.25) 0.291
G16129A 27 31 1.53(0.84-2.78) 0.165 28 28 1.53(0.84-2.79) 0.166
P values were estimated by “chi-square test"; (*) indicated statistical significant (P < 0.05). OR indicates odds ratio; 95% CI, 95% confidence interval.
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CCS of breast cancer CCS of colorectal cancer CCS of thyroid cancer
mtSNPs Controls Cases OR P value Controls Cases OR P value Controls Cases OR P value
(N = 114) (N = 104) (95%CI) (N = 125) (N = 108) (95%CI) (N = 138) (N = 100) (95%CI)
T16140C 11 7 0.68(0.25-1.81) 0.434 13 14 1.28(0.58-2.87) 0.542 13 7 0.72(0.28-1.89) 0.507
A16182C 11 18 1.96(0.88-4.37) 0.096 18 11 0.67(0.30-1.50) 0.331 15 13 1.23(0.56-2.71) 0.615
A16183C 29 28 1.08(0.59-1.98) 0.803 36 22 0.63(0.34-1.16) 0.138 32 25 1.10(0.61-2.01) 0.747
T16189C 38 35 1.01(0.58-1.78) 0.960 42 36 0.99(0.57-1.71) 0.966 46 26 0.70(0.40-1.24) 0.224
T16217C 16 11 0.72(0.32-1.64) 0.439 17 9 0.58(0.25-1.36) 0.203 19 9 0.62(0.27-1.43) 0.260
C16223T 69 68 1.23(0.71-2.14) 0.458 73 66 1.12(0.66-1.89) 0.674 83 62 1.08(0.64-1.83) 0.772
T16298C 10 12 1.36(0.56-3.29) 0.498 10 14 1.71(0.73-4.03) 0.214 12 6 0.67(0.24-1.85) 0.438
T16304C 11 13 1.33(0.57-3.13) 0.502 23 14 0.66(0.32-1.36) 0.257 28 13 0.59(0.29-1.20) 0.142
T16311C 20 17 0.92(0.45-1.87) 0.814 23 13 0.61(0.29-1.27) 0.180 19 9 0.62(0.27-1.43) 0.260
G16319A 15 13 0.94(0.43-2.09) 0.885 11 18 2.07(0.93-4.61) 0.070 17 16 1.36(0.65-2.83) 0.417
T146C 16 17 1.20(0.57-2.51) 0.634 13 17 1.61(0.74-3.49) 0.225 20 10 0.66(0.29-1.47) 0.303
C150T 28 33 1.43(0.79-2.59) 0.239 33 25 0.84(0.46-1.53) 0.567 33 22 0.90(0.49-1.66) 0.730
T152C 20 23 1.34(0.68-2.61) 0.397 27 26 1.15(0.62-2.13) 0.653 33 31 1.43(0.80-2.55) 0.224
249delA 20 19 1.05(0.53-2.10) 0.889 25 23 1.08(0.57-2.04) 0.807 31 13 0.52(0.25-1.05) 0.063
524delAC 42 27 0.60(0.34-1.07) 0.084 43 33 0.84(0.48-1.46) 0.532 52 42 1.20(0.71-2.0) 0.501
P values were estimated by “chi-square test"; (*) indicated statistical significant (P < 0.05). OR indicates odds ratio; 95% CI, 95% confidence interval.3
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0this process include the cellular thresholds required to
activate those pathways, which also could be tissue-
specific.
Another major finding of our studies is that mtDNA
haplogroups D4a and D5 were associated with an
increased risk of breast cancer and thyroid cancer,
respectively, in the southern Chinese population. In a
previous investigation on longevity in a Japanese popu-
lation, D4a and D5 were found to be enriched in cen-
tenarians[25]. It was further hypothesized that the
replacement of Ile78Thr in the cytochrome b subunit
of respiratory complex III in D4a, and Ile278Val in
ND2 and Ile423Val in ND4 of complex I in D5 could
play roles in modulating ROS production[25,26]. It is
worth noting that aging and cancer could both result
from the deregulation of cell homeostasis[49]. The reg-
ulation of homeostasis is mostly achieved by the
balanced control of cell death and cell proliferation.
Thus it is possible that the long lifespan observed to
be associated with D4a and D5 could be achieved at
the expense of higher cancer incidence. Consistent
with this notion, it was reported that D5a and D4a are
risk factors of esophageal cancer in the Chaoshan and
Taihang Mountain areas of southern China[35]. In
fact, most patients and control subjects identified as
D5 in our study are indeed D5a, as most of the D5
sub-haplogroup individuals in southern China could be
further designated as D5a. In another study, hap-
logroup D was suggested as a likely risk factor for
endometrial cancer in southwestern China[50].
In addition to 10398 variants, the functional implica-
tions of the haplopgroup J defining mtSNP C295T in
the D-loop region were also examined. It was reported
that C295T was associated with an increased binding of
TFAM (transcription factor A, mitochondrial), and as a
result, cybrids with haplogroup J had a significantly
increased mtDNA copy number compared with those
carrying haplogroup H[51]. It is possible that the combi-
nation of 16362C and 16129A in the D-loop region
observed in our study could have an effect on mtDNA
replication and/or transcription as well.
Furthermore, a major finding of our study suggested
that mitochondrial macro-haplogroup M or mtSNP
10398G could exert different effects under different
nuclear background. This is consistent with results of
our previous study in which we found that mtDNA
mutations, probably mediated by ROS and apoptosis,
can play different roles in different stages of cancer
development[52]. The potential regulation of tumorigen-
esis by mtDNA haplogroups or mtSNPs is likely facili-
tated by nuclear encoded factors, as evidenced by the
tissue-specific and population-specific features of
mtDNA haplogroups. To test this hypothesis, it would
be necessary to extend our investigation to include a
greater diversity of populations and cancer types, and
more importantly complementary functional assays.
Finally, based on results obtained from this study, an
extended investigation including larger cohort and with
more cancer types would be warranted to reveal further
the interaction between mitochondrial and nuclear
genome in cancer cells.
Conclusions
We found macro-haplogroup M and its sub-haplogroup
D5 exhibited an increased risk of breast cancer occur-
rence but haplogroup M was decreased in the metastatic
group. On the other hand, haplogroup D4a was asso-
ciated with an increased risk of thyroid cancer, while no
significant correlation has been detected between any
mtDNA haplogroups and colorectal cancer occurrence.
Our data indicate that mitochondrial haplogroups could
have a tissue-specific, population-specific and stage-
specific role in modulating cancer development.
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